Literature DB >> 7743575

Acute quadriparesis in an asthmatic treated with atracurium.

C P Tousignant1, D R Bevan, A A Eisen, J C Fenwick, M G Tweedale.   

Abstract

An 18-yr-old male asthmatic was paralyzed with atracurium for a period of seven days to facilitate mechanical pulmonary ventilation. After withdrawal of the muscle relaxant, train-of-four neuromuscular monitoring demonstrated rapid recovery of normal function. Three days later he developed acute quadriparesis without respiratory compromise. Electrophysiological studies showed normal conduction velocities, low compound muscle action potential amplitudes and evidence of denervation. Most cases of post-ventilatory weakness in the ICU involve the use of vecuronium and pancuronium. It has been suggested that the steroid nucleus in these muscle relaxants may be responsible. Our patient developed generalised weakness after treatment with atracurium, a benzylisoquinolinium muscle relaxant. Thus, it appears that the steroid nucleus of vecuronium and pancuronium is not essential in causing post-ventilatory weakness.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743575     DOI: 10.1007/BF03010682

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  19 in total

1.  Prolonged weakness after long-term infusion of vecuronium bromide.

Authors:  Y Kupfer; T Namba; E Kaldawi; S Tessler
Journal:  Ann Intern Med       Date:  1992-09-15       Impact factor: 25.391

2.  Prolonged paralysis after treatment with neuromuscular junction blocking agents.

Authors:  J L Gooch; M R Suchyta; J M Balbierz; J H Petajan; T P Clemmer
Journal:  Crit Care Med       Date:  1991-09       Impact factor: 7.598

3.  Critically ill patients with newly acquired weakness: the clinicopathological spectrum.

Authors:  D A Chad; D Lacomis
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

4.  Complete ophthalmoplegia as a complication of acute corticosteroid- and pancuronium-associated myopathy.

Authors:  L D Sitwell; B G Weinshenker; V Monpetit; D Reid
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

5.  Critical illness polyneuropathy. A complication of sepsis and multiple organ failure.

Authors:  D W Zochodne; C F Bolton; G A Wells; J J Gilbert; A F Hahn; J D Brown; W A Sibbald
Journal:  Brain       Date:  1987-08       Impact factor: 13.501

Review 6.  Rehabilitation of patients with quadriparesis after treatment of status asthmaticus with neuromuscular blocking agents and high-dose corticosteroids.

Authors:  S Apte-Kakade
Journal:  Arch Phys Med Rehabil       Date:  1991-11       Impact factor: 3.966

7.  A possible role for glucocorticoids in denervation atrophy.

Authors:  D C DuBois; R R Almon
Journal:  Muscle Nerve       Date:  1981 Sep-Oct       Impact factor: 3.217

8.  Acute respiratory failure neuropathy: a variant of critical illness polyneuropathy.

Authors:  K C Gorson; A H Ropper
Journal:  Crit Care Med       Date:  1993-02       Impact factor: 7.598

9.  Myopathy in severe asthma.

Authors:  J A Douglass; D V Tuxen; M Horne; C D Scheinkestel; M Weinmann; D Czarny; G Bowes
Journal:  Am Rev Respir Dis       Date:  1992-08

10.  Acute steroid-induced tetraplegia following status asthmaticus.

Authors:  P W Kaplan; W Rocha; D B Sanders; B D'Souza; A Spock
Journal:  Pediatrics       Date:  1986-07       Impact factor: 7.124

View more
  3 in total

1.  Infusions of rocuronium and cisatracurium exert different effects on rat diaphragm function.

Authors:  Dries Testelmans; Karen Maes; Patrick Wouters; Scott K Powers; Marc Decramer; Ghislaine Gayan-Ramirez
Journal:  Intensive Care Med       Date:  2007-03-15       Impact factor: 17.440

2.  Patterns of neurophysiological abnormality in prolonged critical illness.

Authors:  J H Coakley; K Nagendran; G D Yarwood; M Honavar; C J Hinds
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

3.  A fresh look at paralytics in the critically ill: real promise and real concern.

Authors:  David Price; Nicholas J Kenyon; Nicholas Stollenwerk
Journal:  Ann Intensive Care       Date:  2012-10-12       Impact factor: 6.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.